SnapShot: Bladder Cancer

Carolyn Hurst; Jonathan Rosenberg; Margaret Knowles

doi:10.1016/j.ccell.2018.07.013

SnapShot: Bladder Cancer

Cancer Cell. 2018 Aug 13;34(2):350-350.e1. doi: 10.1016/j.ccell.2018.07.013.

Authors

Carolyn Hurst¹, Jonathan Rosenberg², Margaret Knowles¹

Affiliations

¹ Leeds Institute of Cancer and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
² Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 353 E 68(th) Street, New York, NY 10065, USA.

PMID: 30107181
DOI: 10.1016/j.ccell.2018.07.013

Abstract

Bladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes. Recent genomic and transcriptomic data have significantly improved tumor sub-classification and prognostication for both patient groups and are informing improved approaches to treatment of muscle-invasive disease. To view this SnapShot, open or download the PDF.